A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck.

Background: An open-label, multicenter, single-arm phase II trial was conducted to investigate the clinical activity of dacomitinib in recurrent/metastatic squamous-cell carcinoma of the head and neck (RM-SCCHN).

Patients And Methods: Eligible patients were administered dacomitinib at 45 mg orally daily, in 21-day cycles. Primary end point was objective response rate.

Similarities and differences between traumatic and emotional memories: review and directions for future research.

The authors review theory and empirical research on the characteristics of memories for traumatic versus emotional events, with the goal of bringing together the cognitive and clinical perspectives on this issue. They consider the most important approaches to the study of traumatic and emotional memory and summarize the results of recent studies that have compared autobiographical recollections of traumatic and nontraumatic emotional experiences (positive and negative), either in nonclinical or clinical samples. Overall, findings from the current empirical literature are inconsistent.

Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery.

Background: Early after coronary artery bypass surgery (CABG), activation of numerous neurohumoral and endogenous vasodilator systems occurs that could be influenced favorably by angiotensin-converting enzyme inhibitors.

Methods And Results: The Ischemia Management with Accupril post-bypass Graft via Inhibition of the coNverting Enzyme (IMAGINE) trial tested whether early initiation (< or = 7 days) of an angiotensin-converting enzyme inhibitor after CABG reduced cardiovascular events in stable patients with left ventricular ejection fraction > or = 40%. The trial was a double-blind, placebo-controlled study of 2553 patients randomly assigned to quinapril, target dose 40 mg/d, or placebo, who were followed up to a maximum of 43 months.

Rorschach Comprehensive System data for a sample of 100 adult nonpatients from the Belgian French-speaking community.

This article presents normative data for the Rorschach Comprehensive System (CS) on 100 adult nonpatients from the Belgian French-speaking community. We compare our Belgian sample to a French one (Sultan et al., 2004), data of Exner's (Exner & Erdberg, 2005) and a Californian sample (Shaffer, Erdberg, & Haroian, 1999).